Already have an account? Sign in.
Innate Pharma Receives Strong Buy Recommendation for Cancer Drug Potential
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.
Palo Alto Networks and other cyber stocks surged after DHS Secretary Mullin warned of rising AI-powered attacks on U.S. critical infrastructure.
BETA Technologies shares drop after Gotham City Research challenges the 336-mile range claim, certification progress, and $10 valuation.
Recursion said the FDA agreed on a Phase 3 trial design for REC-4881 in FAP, a rare disease with no approved drugs.
Be the first to know when deals break, stocks move, or biotech headlines hit.